| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $49,931,130 | 42 | 100 |
| Stephenson Pamela | Chief Commercial Officer | 0 | $0 | 1 | $347,679 | $-347,679 |
| Franchi Jean M. | Chief Financial Officer | 0 | $0 | 5 | $1.2M | $-1.2M |
| Khara Rahul | Chief Legal Officer | 0 | $0 | 6 | $1.81M | $-1.81M |
| Savage William Jacob | Chief Medical Officer | 0 | $0 | 4 | $2.27M | $-2.27M |
| Yu Jonathan Yen-Wen | Chief Operating Officer | 0 | $0 | 9 | $5.59M | $-5.59M |
| Quisel John D | Chief Executive Officer | 0 | $0 | 5 | $12.03M | $-12.03M |
| Bitterman Kevin | director | 0 | $0 | 12 | $26.68M | $-26.68M |
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Over the last 12 months, insiders at Disc Medicine, Inc. have bought $0 and sold $49.93M worth of Disc Medicine, Inc. stock.
On average, over the past 5 years, insiders at Disc Medicine, Inc. have bought $12M and sold $43.19M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 222,223 shares for transaction amount of $8M was made by Bitterman Kevin (director) on 2024‑06‑17.
| 2026-10-21 | Sale | Bitterman Kevin | director | 25,519 0.0702% | $80.23 | $2.05M | +5.13% | |
| 2026-10-20 | Sale | Bitterman Kevin | director | 5,312 0.0139% | $79.95 | $424,694 | -0.28% | |
| 2026-10-19 | Sale | Bitterman Kevin | director | 10,994 0.029% | $79.97 | $879,190 | +0.70% | |
| 2026-09-11 | Sale | Bitterman Kevin | director | 27,136 0.0702% | $70.11 | $1.9M | -3.94% | |
| 2026-09-04 | Sale | Bitterman Kevin | director | 1,689 0.0044% | $79.96 | $135,052 | -13.56% | |
| 2026-09-03 | Sale | Bitterman Kevin | director | 5,203 0.0137% | $79.98 | $416,136 | -13.66% | |
| 2026-09-02 | Sale | Bitterman Kevin | director | 49,164 0.1282% | $80.17 | $3.94M | -14.34% | |
| 2026-09-01 | Sale | Bitterman Kevin | director | 129 0.0003% | $79.95 | $10,314 | -12.62% | |
| 2026-08-25 | Sale | Yu Jonathan Yen-Wen | Chief Operating Officer | 8,796 0.0231% | $83.12 | $731,092 | -15.63% | |
| 2026-08-24 | Sale | Yu Jonathan Yen-Wen | Chief Operating Officer | 300 0.0008% | $82.53 | $24,760 | -13.77% | |
| 2026-08-17 | Sale | Quisel John D | Chief Executive Officer | 33,000 0.0843% | $79.15 | $2.61M | -6.92% | |
| 2026-08-12 | Sale | Yu Jonathan Yen-Wen | Chief Operating Officer | 804 0.0021% | $82.64 | $66,445 | -6.30% | |
| 2026-08-06 | Sale | Khara Rahul | Chief Legal Officer | 5,000 0.0135% | $80.00 | $400,000 | -0.99% | |
| 2026-07-13 | Sale | Quisel John D | Chief Executive Officer | 33,000 0.0852% | $74.96 | $2.47M | +0.04% | |
| 2026-07-07 | Sale | Yu Jonathan Yen-Wen | Chief Operating Officer | 100 0.0003% | $82.50 | $8,250 | -4.61% | |
| 2026-06-29 | Sale | Khara Rahul | Chief Legal Officer | 1,649 0.0043% | $75.00 | $123,675 | +2.21% | |
| 2026-06-26 | Sale | Yu Jonathan Yen-Wen | Chief Operating Officer | 300 0.0008% | $72.50 | $21,750 | +1.75% | |
| 2026-06-22 | Sale | Yu Jonathan Yen-Wen | Chief Operating Officer | 9,700 0.0261% | $72.66 | $704,795 | +7.33% | |
| 2026-06-18 | Sale | Quisel John D | Chief Executive Officer | 34,000 0.0883% | $70.21 | $2.39M | +7.33% | |
| 2026-06-18 | Sale | Khara Rahul | Chief Legal Officer | 7,500 0.0195% | $70.22 | $526,661 | +7.33% |
| Bitterman Kevin | director | 12991 0.0338% | $1.05M | 1 | 26 | +10.7% |
| AI DMI LLC | 10 percent owner | 3141759 8.1832% | $254.99M | 1 | 0 | +100.92% |
| ORBIMED ADVISORS LLC | director | 186541 0.4859% | $15.14M | 1 | 7 | +10.7% |
| Ashiya Mona | director | 186541 0.4859% | $15.14M | 1 | 7 | +10.7% |
$52,263,649 | 70 | 1.18% | $2.49B | |
$586,486,795 | 47 | 4.28% | $2.38B | |
$104,428,685 | 44 | 22.55% | $3.78B | |
$1,275,975,557 | 32 | 19.44% | $3.54B | |
$105,063,207 | 29 | 14.02% | $2.36B |
| Increased Positions | 129 | +94.16% | 9M | +25.77% |
| Decreased Positions | 59 | -43.07% | 5M | -13.8% |
| New Positions | 43 | New | 3M | New |
| Sold Out Positions | 12 | Sold Out | 1M | Sold Out |
| Total Postitions | 207 | +51.09% | 38M | +11.97% |
| Fmr Llc | $390,322.00 | 12.99% | 4.94M | +2M | +52.05% | 2025-09-30 |
| Atlas Venture Life Science Advisors, Llc | $169,460.00 | 5.64% | 2.14M | -241,839 | -10.14% | 2025-09-30 |
| Blackrock, Inc. | $159,705.00 | 5.31% | 2.02M | -25,544 | -1.25% | 2025-09-30 |
| Ra Capital Management, L.P. | $124,733.00 | 4.15% | 1.58M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $114,527.00 | 3.81% | 1.45M | +51,323 | +3.67% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $113,774.00 | 3.79% | 1.44M | -216,300 | -13.07% | 2025-09-30 |
| Orbimed Advisors Llc | $111,914.00 | 3.72% | 1.42M | 0 | 0% | 2025-09-30 |
| Wellington Management Group Llp | $111,523.00 | 3.71% | 1.41M | -22,013 | -1.54% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $104,907.00 | 3.49% | 1.33M | -189,196 | -12.48% | 2025-09-30 |
| State Street Corp | $82,696.00 | 2.75% | 1.05M | +115,829 | +12.46% | 2025-09-30 |